Quetiapine 치료 중 발생한무증상 갑상선 기능저하증 1례
Subclinical Hypothyroidism during Quetiapine Treatment: A Case Report
0
조회
0
다운로드
1
인용
0
참고문헌
초록
Quetiapine은 부작용이 심하지 않은 비정형 항정신병 약물이다. 그러나 최근 연구들에서 quetiapine 치료와 관련된 갑상선 기능이상에 대한 사례들이 보고되었다. 저자들은 양극성 장애 환자에서 quetiapine 치료 중 무증상 갑상선 기능저하증이 발생한 사례를 보고하고자 한다. 환자는 antithyroglobulin 항체를 포함한 갑상선 기능검사 상에서 이상 소견을 보였으나, 갑상선 이상과 관련된 뚜렷한 임상적 증상은 보이지 않았다. Quetiapine 투여를 중지하자 갑상선 기능 검사 상의 비정상적인 수치는 곧바로 정상 수준으로 회복되었다. Quetiapine 치료 중 발생한 무증상 갑상선 기능 이상은 아마도 자가면역 과정과 관련되어 있을 것으로 생각된다.
Abstract
Quetiapine is an atypical antipsychotic drug with a benign side effect profile. However, recent studies have reported that thyroid dysfunction is associated with quetiapine treatment. The authors report a patient with DSM-IV bipolar I disorder who developed subclinical hypothyroidism during quetiapine treatment. The patient showed no significant clinical symptoms, but only abnormal thyroid function test findings including antithyroglobulin antibody. The abnormal thyroid function test findings were normalized after discontinuation of quetiapine. The subclinical hypothyroidism developed during quetiapine treatment may be associated with autoimmune process.
참고문헌 (22)
- Tohen M, "Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.", 156, pp.702~709 (1999)
- Hirschfeld RM, "The efficacy of atypical antipsychotics in bipolar disorders.", 64(8), pp.15~21 (2003)
- McElroy SL, "Pharmacologic agents for the treatment of acute bipolar mania.", 48, pp.539~557 (2000)
- Goodwin GM, "Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology.", 17, pp.149~173 (2003)
- Grunze H, "World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression.", 3, pp.115~124 (2003)
- Grunze H, "The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania.", 4, pp.5~13 (2003)
- Zarate CA, Jr, "Clinical predictors of acute response with quetiapine in psychotic mood disorders.", 61, pp.185~189 (2000)
- McConville BJ, "Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders.", 61, pp.252~260 (2000)
- Garver DL, "Review of quetiapine side effects", 61(8), pp.31~33 (2000)
- Feret BM, "Possible hypothyroidism associated with quetiapine", 34, pp.483~486 (2000)
- Ramaswamy S, "Quetiapine-induced hypothyroidism.", 30, pp.57~ (2005)
- Liappas J, "Hypothyroidism induced by quetiapine: a case report.", 26, pp.208~209 (2006)
- Choi SH, "Seizure and Thyroid Dysfunction Associated with High Dose of Quetiapine: Case Report.", 45, pp.481~483 (2006)
- APA, "Diagnostic and statistical manual of mental disorders" (1994), American Psychiatric Press
- Keck PE, Jr, "The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania.", 66, pp.5~11 (2005)
- Bocchetta A, "The course of thyroid abnormalities during lithium treatment", pp.38~41
- Calabrese JR, "Autoimmune thyroiditis in manic-depressive patients treated with lithium", pp.1318~1321
- Lee S, "Thyroid abnormalities during chronic lithium treatment in Hong Kong Chinese", pp.173~178
- Kelly DL, "Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine.", 66, pp.80~84 (2005)
- Extein I, "Does subclinical hypothyroidism predispose to tricyclic-induced rapid mood cycles?", pp.290~291
- Bauer MS, "Treatment of refractory rapid cycling with high-dose levothyroxine", pp.435~440
- Gharib H, "Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society.", 90, pp.581~585 (2005)